Nebenwirkungen · Foclivia
Foclivia suspension for injection in pre-filled syringe Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) · Abschnitt 4.8 · PDF-Seite 5
HOS-212734 · Präparat HOS-154968
The safety of H5N1 vaccine combined with MF59C.1 adjuvant (7.5 or 15 micrograms haemagglutinin, HA) containing either the A/turkey/Turkey/1/2005 or the A/Vietnam/1194/2004 strain has been evaluated in nine clinical trials in healthy subjects involving 5055 adults, elderly and children. There were 4041 adult subjects 18 to 60 years of age and 540 elderly subjects 61 years of age and above. In the paediatric population, there were 214 subjects 6 to 35 months of age, 167 subjects 3 to 8 years of age and 93 subjects 9 to 17 years of age.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-16T09:31:00Z · SHA-256 03d4abeebc6353c3f61b12133eba34d04f4ddb38a99b9dd429b813672ea12588 · Passage 16a91d06d82ae5ef74e76f9964de15cd5790b7c147ea755eefef78549042293b · Zeichen 27–566 im Abschnitt